Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.
We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no toxic deaths and five patients were able to proceed to high dose therapy with autologous bone marrow transplantation (ABMT).
Department of Haematology, Taunton and Somerset Hospital, U.K.
D S
DS
Richardson
M
M
Tighe
G
G
Cull
S A
SA
Johnson
M J
MJ
Phillips
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011239:Prednisolone / Q000008:administration & dosage; D016879:Salvage Therapy; D016896:Treatment Outcome
D005047:Etoposide; D011239:Prednisolone; D016190:Carboplatin; D007069:Ifosfamide